Literature DB >> 14981063

Causes and consequences of increased sympathetic activity in renal disease.

Jaap A Joles1, Hein A Koomans.   

Abstract

Much evidence indicates increased sympathetic nervous activity (SNA) in renal disease. Renal ischemia is probably a primary event leading to increased SNA. Increased SNA often occurs in association with hypertension. However, the deleterious effect of increased SNA on the diseased kidney is not only caused by hypertension. Another characteristic of renal disease is unbalanced nitric oxide (NO) and angiotensin (Ang) activity. Increased SNA in renal disease may be sustained because a state of NO-Ang II unbalance is also present in the hypothalamus. Very few studies have directly compared the efficacy of adrenergic blockade with other renoprotective measures. Third-generation beta-blockers seem to have more protective effects than traditional beta-blockers, possibly via stimulation of NO release. Although it has been extensively documented that muscle SNA is increased in chronic renal failure, data on renal SNA and cardiac SNA are not available for these patients before end-stage renal disease. It is also unknown whether additional treatment with third-generation beta-blockers can delay the progression of renal injury and prevent cardiac injury in chronic renal failure more efficiently than conventional treatment with angiotensin-converting enzyme inhibitors only.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981063     DOI: 10.1161/01.HYP.0000121881.77212.b1

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  50 in total

1.  Hypertension: Renal denervation in chronic kidney disease.

Authors:  Peter J Blankestijn; Jaap A Joles
Journal:  Nat Rev Nephrol       Date:  2012-07-03       Impact factor: 28.314

Review 2.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 3.  Cardiorenal syndrome: still not a defined entity.

Authors:  Carlo Longhini; Christian Molino; Fabio Fabbian
Journal:  Clin Exp Nephrol       Date:  2010-02-20       Impact factor: 2.801

Review 4.  Renal protection in hypertensive patients: selection of antihypertensive therapy.

Authors:  René R Wenzel
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Technical aspects of renal denervation in end-stage renal disease patients with challenging anatomy.

Authors:  Alessio Spinelli; Valerio Da Ros; Daniele Morosetti; Silvia D Onofrio; Valentina Rovella; Nicola Di Daniele; Giovanni Simonetti
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

6.  Synergistical action of the β2 adrenoceptor and fatty acid binding protein 2 polymorphisms on the loss of glomerular filtration rate in Chinese patients with type 2 diabetic nephropathy.

Authors:  Tao Wang; Yan Zhang; Ning Wang; Qiong Liu; ZeKai Wang; Bing Liu; Kai Niu
Journal:  Int Urol Nephrol       Date:  2018-02-05       Impact factor: 2.370

Review 7.  Renal nerves in the maintenance of hypertension: a potential therapeutic target.

Authors:  Richard E Katholi; Krishna J Rocha-Singh; Nilesh J Goswami; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

Review 8.  Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially.

Authors:  Alberto Palazzuoli; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2011-11       Impact factor: 4.214

Review 9.  Angiotensin II, sympathetic nerve activity and chronic heart failure.

Authors:  Yutang Wang; Sai-Wang Seto; Jonathan Golledge
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

10.  A functional polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, dysfunction, and ischemia: data from the heart and soul study.

Authors:  Ramin Farzaneh-Far; Gary V Desir; Beeya Na; Nelson B Schiller; Mary A Whooley
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.